Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis
Pediatric Pulmonology · 2025
DOI: 10.1002/ppul.71280 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, 2025. Verfasst von Susanne Ursula Trost und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Bone Density, Cystic Fibrosis, Body Composition, Aminophenols. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
The approval of cystic fibrosis transmembrane conductance regulator modulators elexacaftor/tezacaftor/ivacaftor (ETI), has significantly improved pulmonary function for people with cystic fibrosis (pwCF). However, the effects on CF‐related bone disease and body composition remain unclear.
Methods
This retrospective real‐world study examined adults with CF who received ETI treatment. Bone density and body composition were measured via dual‐energy X‐ray absorptiometry (DXA) 1.8 (SD 0.7) years before (preDXA) and 1.5 (SD 0.4) years after ETI initiation (postDXA1). In a subgroup, measurements were also available 4 (SD 0.6) years after initiation (postDXA2).
Results
The study included 74 pwCF, of whom 42% were female, with an average age of 38.9 (SD 9.3) years at ETI initiation. Bone density decreased significantly at the spine ( p = 0.02), left hip ( p < 0.01), and right hip ( p < 0.01) from pre‐ to postDXA1. No significant change in bone density was observed when comparing postDXA1 to postDXA2. Body composition analysis revealed significant increases in weight in both females ( p < 0.01) and males ( p < 0.01), as well as increases in fat mass in females ( p < 0.01) and males ( p < 0.01), without significant changes in lean mass ( p = 0.4).
Conclusions
Bone density declined significantly during the study period, with the most pronounced decline occurring in the first 1.5 years after ETI initiation. However, this decline appeared to stabilize in participants with longer follow‐up at 4 years post‐ETI treatment, suggesting potential bone‐protective effects with prolonged therapy. Body weight and fat mass increased early after ETI initiation, suggesting metabolic changes accompanying CFTR modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Minnesota, Minneapolis, Minnesota, USA.
- Clinical and Transitional Science Institute, University of Minnesota, Minneapolis, Minnesota, USA.
ORCID-Profile: Susanne Ursula Trost
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Trost, S. U., Harindhanavudhi, T., Wang, Q., Ankireddypalli, A., Simrah, A., Avula, S., & Moheet, A. (2025). Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. Pediatric Pulmonology. https://doi.org/10.1002/ppul.71280
Vancouver
Trost SU, Harindhanavudhi T, Wang Q, Ankireddypalli A, Simrah A, Avula S, et al. Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis. Pediatric Pulmonology. 2025. doi:10.1002/ppul.71280
BibTeX
@article{Trost2025,
author = {Trost, Susanne Ursula and Harindhanavudhi, Tasma and Wang, Qi and Ankireddypalli, Anvitha and Simrah, Azmi and Avula, Sreekant and Moheet, Amir},
title = {Elexacaftor/Tezacaftor/Ivacaftor Effect on Bone Density and Body Composition: A Retrospective Analysis},
journal = {Pediatric Pulmonology},
year = {2025},
doi = {10.1002/ppul.71280}
}
EUVIMED